Shares of Novavax Inc. (NASDAQ:NVAX) are trading higher Monday morning. The stock is extending its 3

Shares of Novavax are trading higher Monday, extending its 30% monthly gains on COVID-19 vaccine app

U.S. stocks were lower, with the Dow Jones index falling around 400 points on Monday. Shares of A

Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U

Novavax, Inc.'s (NASDAQ:NVAX) partners have received approvals for the Nuvaxovid™ formulation to

COVID-19 remains a public health challenge, particularly among older adults and high-risk population

FDA approves updated COVID-19 vaccines for 2026-'27 season, targeting XFG variant. Limited eligi

The U.S. Food and Drug Administration approved Moderna, Novavax-Sanofi and ​Pfizer-BioNTech's update

Drug stock Novavax Inc (NASDAQ:NVAX) is trading 2.8% lower at $9.18 this afternoon, pulling back fro

Shares of Novavax are trading higher Tuesday morning as buying interest continues across late-stage

Recursion, Novavax and Crispr Therapeutics slip in premarket trading after surging Wednesday on posi

A third drug stock making plenty of progress in today's trading

Shares of Novavax Inc (NASDAQ: NVAX) are trading higher Wednesday. The move comes as a major clinica

https://youtu.be/H_RititNE8U

Novavax beat Q2 earnings and revenue estimates, raises its 2026 adjusted revenue outlook, cuts expen

Novavax NASDAQ: NVAX reported second-quarter 2026 revenue of $57 million and a net loss of $53 milli

Novavax, Inc. (NVAX) Q2 2026 Earnings Call Transcript

Novavax (NVAX) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate

Here is how Novavax (NVAX) and Addus HomeCare (ADUS) have performed compared to their sector so far

Novavax raised its annual revenue forecast after beating quarterly expectations on Thursday, as the

Novavax (NASDAQ:NVAX) raises FY2026 sales outlook from $230.000 million-$270.000 million to $235.000

Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Reven

GAITHERSBURG, Md., July 30, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that t

Novavax is significantly undervalued post-COVID, with a current enterprise value around $716 million

In the most recent trading session, Novavax (NVAX) closed at $7.37, indicating a -1.6% shift from th

Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhi

Novavax (NVAX) reached $7.88 at the closing of the latest trading day, reflecting a -4.02% change co

In the latest trading session, Novavax (NVAX) closed at $8.42, marking a -5.5% move from the previou

Novavax (NVAX) concluded the recent trading session at $9.35, signifying a -1.16% move from its prio

Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhi

Moderna and Novavax stocks climb as investors digest new cases in the hantavirus outbreak.

Moderna is researching hantavirus vaccine with U.S. Army while Novavax stock rises due to increased

TD Cowen analyst Chris LoBianco maintains Novavax (NASDAQ:NVAX) with a Hold and raises the price

Novavax shares rise after Q1 revenue beat; partnerships, credit facility, and technical levels shape

Novavax (NASDAQ:NVAX) affirms FY2026 sales outlook from $230.000 million-$270.000 million to $230.00

Novavax (NASDAQ:NVAX) reported quarterly losses of $(0.06) per share. This is a 102.05 percent decre

https://www.nytimes.com/2026/05/05/us/politics/fda-covid-vaccine-studies.html

Here's a look at the earnings calendar for the week ahead, including reports from Nvidia, Joby,

Pfizer Inc. (PFE) shares are trading higher on Tuesday, as the stock benefits from a price target in

Novavax shares are up on Monday following a licensing agreement with Pfizer for the use of its Matri

After a brief and cautious rebound on Wednesday, risk-off sentiment returned sharply on Thursday, wi

Retail investors are preparing for another busy week of earnings season with more than 1,600 compani

Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease